Michel Ducreux, ESMO 2019 – Treating advanced pancreatic cancer

Treatment of locally advanced pancreatic cancer has really primarily consisted of systemic intravenous chemotherapy. The TIGeR-PaC trial is aiming to assess if an alternative treatment mode, intra-arterial delivery of gemcitabine, improves overall survival. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the […]

Locally advanced pancreatic cancer represents around 30% of all newly diagnosed pancreatic cancers and can be challenging to treat. In this touchONCOLOGY interview, we speak with Dr Michael Pishvaian (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the challenges in the treatment of locally advanced pancreatic cancer. Dr Pishvaian presented an abstract […]

touchONCOLOGY were thrilled to speak to Professor Marcus S Noel (Medstar Georgetown University Hospital, Washington, DC, USA) to summarise the latest developments and data from the ASCO Gastrointestinal Cancers Symposium 2022. Questions       What is the rationale for the use of L-asparaginase in the treatment of pancreatic cancer? 00:22-01:00       Could […]